• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CAI International, Inc. Announces Q1 2021 Financial Release Date and Conference Call

    4/26/21 6:16:00 PM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email

    CAI International, Inc. (CAI) (NYSE:CAI) one of the world's leading transportation finance companies, announces the following earnings release date and conference call:

    EARNINGS RELEASE:

    April 29, 2021 at 4:00 pm ET

     

     

    EVENT:

    CAI Q1 2021 Financial Release Conference Call

     

     

    CALL DATE and TIME:

    April 29, 2021 at 5:00 pm ET

     

     

    DOMESTIC DIAL IN:

    1-888-398-8098

     

     

    INTERNATIONAL

     

    DIAL IN:

    1-707-287-9363

     

     

    LIVE WEBCAST:

    www.capps.com and click on the "Investors" tab

    If you are unable to participate during the live conference call and webcast, the call will be archived at www.capps.com for 30 days (click the "Investors" tab).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005913/en/

    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    2/17/2026$26.00Outperform
    Robert W. Baird
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    More analyst ratings

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

    Caris AI Insights are proprietary algorithms only available to Caris Life Sciences customers and not achievable through small panelsIRVING, Texas, March 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the addition of two new Caris AI Insights™ signatures included in the Caris Molecular Tumor Board Report. These signatures assess the risk of patients developing brain metastases in breast and lung cancer. The addition of these two signatures brings the total number of proprietary Caris AI insights to seven, providing deeper insights to physicians and patients. This report, avail

    3/26/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

    IRVING, Texas, March 25, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance® (Caris POA®) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026. These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcrip

    3/25/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

    Caris reinforces the value of Whole Exome Sequencing and Whole Transcriptome Sequencing testing for cancer patientsIRVING, Texas, March 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, is recognizing Colorectal Cancer Awareness Month by highlighting the critical role of DPYD testing in helping to inform treatment for patients with colorectal cancer. Colorectal cancer remains one of the most commonly diagnosed cancers in the United States and is a leading cause of cancer-relat

    3/24/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    SEC Filings

    View All

    Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    2/26/26 4:11:03 PM ET
    $CAI
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.

    SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)

    2/13/26 4:30:03 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    2/5/26 1:20:38 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Spetzler David Baxley was granted 83,162 shares, increasing direct ownership by 18% to 543,939 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 5:59:58 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 4 filed by Caris Life Sciences Inc.

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:01:21 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel was granted 63,971 shares, increasing direct ownership by 52% to 187,562 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:00:25 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Caris Life Sciences with a new price target

    Robert W. Baird initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $26.00

    2/17/26 8:16:25 AM ET
    $CAI
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Caris Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00

    12/2/25 8:24:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

    IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will

    10/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care